On September 24, 2009, Hanford Pharmaceuticals (“Hanford” or the “Company”) completed the sale of its Cephalosporin manufacturing facility in Syracuse, NY, an asset that had been under-performing for quite some time. As part of the deal, Hanford will continue to manufacture mastitis products in the facility. With this divestiture, the Company is now better positioned not only to meet increased sales demand for its core business products, but also to expand into new areas outside of its current market space.
Hanford is committed to increasing diversification of its product and service offerings and understands that its 30 years of experience in aseptic processing can be more broadly utilized. In order to capitalize on its experience, the Company has acquired an 84,000 square-foot facility and is currently developing the space for manufacturing, warehousing and laboratory support services. This facility will include both aseptic processing capability as well as space that can be used for non-sterile product manufacturing. Additionally, the facility will provide the space necessary to increase Hanford’s ability to offer its broad range of contract pharmaceutical support services, including Validation Services, Analytical Methods Development, Regulatory and Document Support, Quality Control Testing and OSHA/FDA Required Safety and GMP Training, to name just a few.
Hanford’s contract manufacturing ramp-up calls for the installation of an aseptic filling and packaging line capable of lot sizes of up to 100,000 units, which will be able to handle vial sizes of 2-100mL. This however, is only the start. The facility has sufficient space to accommodate multiple production installations with both clinical and commercial-scale output capabilities.